Background: Irritable bowel syndrome affects one in five Australians, with abdominal pain as one of the main symptoms. Lactoferrin, found in milk, is known for its anti-inflammatory properties, and the development of ...Background: Irritable bowel syndrome affects one in five Australians, with abdominal pain as one of the main symptoms. Lactoferrin, found in milk, is known for its anti-inflammatory properties, and the development of a novel microencapsulated form, Inferrin<sup>TM</sup>, may be useful in the treatment of irritable bowel syndrome symptoms. The current study aimed to study the effectiveness of Inferrin<sup>TM</sup> compared to lactoferrin and a placebo on irritable bowel syndrome symptoms. Methods: Sixty-eight male and female participants over 18 years of age were recruited to complete 8 weeks of supplementation with either Inferrin<sup>TM</sup>, lactoferrin, or a matched placebo. Outcomes were measured at baseline, week 4, and week 8. Results: There was a decrease from baseline across all groups in IBS symptom severity at weeks 4 and 8, as well as improvements in QOL scores. Lactoferrin and Inferrin<sup>TM</sup> groups had a significant reduction from baseline to week 8 in weekly stool frequency. Conclusions: Overall, lactoferrin and Inferrin<sup>TM</sup> appeared to have an effect in decreasing symptoms of IBS and weekly stool frequency.展开更多
文摘Background: Irritable bowel syndrome affects one in five Australians, with abdominal pain as one of the main symptoms. Lactoferrin, found in milk, is known for its anti-inflammatory properties, and the development of a novel microencapsulated form, Inferrin<sup>TM</sup>, may be useful in the treatment of irritable bowel syndrome symptoms. The current study aimed to study the effectiveness of Inferrin<sup>TM</sup> compared to lactoferrin and a placebo on irritable bowel syndrome symptoms. Methods: Sixty-eight male and female participants over 18 years of age were recruited to complete 8 weeks of supplementation with either Inferrin<sup>TM</sup>, lactoferrin, or a matched placebo. Outcomes were measured at baseline, week 4, and week 8. Results: There was a decrease from baseline across all groups in IBS symptom severity at weeks 4 and 8, as well as improvements in QOL scores. Lactoferrin and Inferrin<sup>TM</sup> groups had a significant reduction from baseline to week 8 in weekly stool frequency. Conclusions: Overall, lactoferrin and Inferrin<sup>TM</sup> appeared to have an effect in decreasing symptoms of IBS and weekly stool frequency.
